The numbers tell a story of contradiction. Intuitive Surgical smashed second-quarter earnings estimates, yet its stock has been cut nearly in half from January’s peak. On Thursday, shares closed at €292.05 in European trading, down 2.2% on the day and within a hair’s breadth of their 52-week low of €289.05. The year-to-date decline now stands at 40.4%, a brutal reversal for a company that began 2026 trading at €516.50.
What makes the selloff puzzling is the underlying financial performance. For the quarter ended June 30, revenue climbed 19% to $2.89 billion, beating the analyst consensus of $2.82 billion. Adjusted net income hit $1 billion, or $2.80 per share, well ahead of the $2.51 per share that Wall Street had penciled in. By any conventional measure, this was a beat.
Yet the market’s gaze has fixed on what comes next — and the outlook carries cracks that investors cannot ignore.
Growth Deceleration and a Crowded Operating Room
The core concern centers on procedure growth for Intuitive’s da Vinci surgical systems. Management guided for full-year procedure expansion of 13.5% to 15.5%, with a midpoint of 14.5%. But the second quarter revealed a clear slowdown: U.S. procedure growth slipped to 12%, down from 14% in the first quarter. The company’s finance team has pointed to two specific drags: the expiration of enhanced health insurance subsidies tied to the Affordable Care Act, and the ripple effects of GLP-1 weight-loss drugs, which are reducing the volume of bariatric surgeries.
Competition is also intensifying. The FDA recently granted Johnson & Johnson a De Novo clearance for its OTTAVA robotic surgical system, which covers ten upper-abdominal procedures and boasts a 30% to 50% smaller operating-room footprint by integrating four robotic arms directly into the surgical table. J&J plans a phased U.S. launch with select hospitals. Separately, Momentis Surgical received FDA clearance for the multiport configuration of its Anovo system, which claims to be the first robotic platform to combine natural-orifice, single-port, and multiport procedures. Notably, Momentis’s board includes Frederic Moll, a co-founder of Intuitive Surgical.
Analysts at ICR note that Medtech stocks are currently trading at 15 times forward earnings — a 30% discount to the S&P 500 and the lowest valuation in three decades. Yet the same research points to resilient hospital investment budgets: 77% of hospital CFOs surveyed plan to increase capital spending over the next 12 months. For Intuitive, the installed base of da Vinci systems has grown 12% year-over-year to 11,710 units, with 246 of the newer da Vinci 5 platform added in the second quarter alone. The company has also filed a 510(k) application with the FDA for a non-commercial flexible robotic endoscope aimed at gastrointestinal procedures.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
Insider Selling Meets Institutional Accumulation
The divergence in investor behavior adds another layer. While retail shareholders have been dumping the stock, large institutional players have been quietly building positions. Dimensional Fund Advisors increased its stake by 3.6% in the first quarter to roughly 645,181 shares. NewEdge Wealth made a more aggressive move, expanding its holding by 21.6% over the same period.
Inside the company, the signals are mixed. Director Amy Ladd sold 119 shares at $463.50, while SVP Iman Jeddi offloaded 5,625 shares at $420.55. These insider sales, while not massive in scale, add to the cautious sentiment.
The analyst community remains broadly constructive, with a majority of buy ratings and only a single sell recommendation. Simply Wall St’s valuation model pegged the stock’s fair value well above its current trading level, though it also flagged a price-to-earnings ratio of 37.4 — significantly higher than the industry median of 26.5.
Technical Signals Point to an Oversold Bounce
On a purely technical basis, the stock looks stretched. The 14-day relative strength index sits at 29.3, a level that typically signals oversold conditions and often precedes a pause in selling. The shares are trading roughly 18% below their 50-day moving average and nearly 30% below the 200-day average. Such dislocations have historically attracted bargain hunters.
But the fundamental picture remains clouded. The market capitalization has shrunk to approximately €109 billion, and the trajectory of U.S. procedure growth — especially as J&J and Momentis begin to commercialize their competing systems — will determine whether the current lows represent a buying opportunity or a warning of further downside. For now, the stock is caught between strong quarterly execution and a forward outlook that has yet to convince the broader market.
Ad
Intuitive Surgical Stock: Buy or Sell?! New Intuitive Surgical Analysis from July 24 delivers the answer:
The latest Intuitive Surgical figures speak for themselves: Urgent action needed for Intuitive Surgical investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 24.
Intuitive Surgical: Buy or sell? Read more here...
